Biotech startup OncoSenX is raising more cash to help support its pipeline of therapeutics that aim to kill cancer cells based on their genetics.
- Its technology targets solid tumors based on a patented lipid nanoparticle gene delivery system and a highly targeted DNA payload.
- The Seattle-based company just extended its oversubscribed SAFE (Simple Agreement for Future Equity) to allow for more capital, confirmed CEO Matthew Scholz. It is also planning on raising a $30 million Series A round to support its Phase I clinical trial.
- OncoSenX is a spinout out of Oisin Biotechnologies, a 5-year-old Seattle company also led by Scholz, a veteran biotech entrepreneur. Gary Hudson, a private spaceflight entrepreneur, co-founded Oisin with Scholz and is a board member at OncoSenX, which has raised $4.1 million to date and has six employees.
